Orthopedic medical device company with 5 new biomimetic spine implants (GelStix, GelFix, GelPerc, EnGuard, and GelGuard) entering US clinical trials and/or 510ks. All 5 implants have been approved in Europe. They are indicated for treating low back pain due to degenerative disc disease, spinal stenosis, facet joint syndrome, and epidural fibrosis. GelActive Spine acquired the assets from Replication Medical and is the exclusive licensee. We have an experienced team of orthopedic experts with extensive industry knowledge and a multiple product pipeline with long-term clinical efficacy and safety data. Our patented proprietary technology platform, 'Modified' HPAN Viscoelastic Swellable Radially-compressed Hydrogel, is extremely unique as a biomaterial and a product engine with applications in ortho, neuro, and vascular-surgery. Our clinical value proposition is that our biomimetic implants are considerably less prone to complications than current metal and hard plastic implants, less expensive for patients and payors, less invasive, and are implanted via injectable, percutaneous, and MIS procedures rather than open surgery.